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Background: Donepezil (23 mg/day) is approved by the US Food and Drug Administration for the treatment of
patients with moderate to severe Alzheimer’s disease (AD). Approval was based on results from a 24-week,
randomized, double-blind study of patients who were stable on donepezil 10 mg/day and randomized 2:1 to either
increase their donepezil dose to 23 mg/day or continue taking 10 mg/day. The objective of this study was to assess
the long-term safety and tolerability of donepezil 23 mg/day in patients with moderate to severe AD.
Methods: Patients who completed the double-blind study and were eligible could enroll into a 12-month
extension study of open-label donepezil 23 mg/day. Clinic visits took place at open-label baseline and at months 3,
6, 9, and 12. Safety analyses comprised examination of the incidence, severity, and timing of treatment-emergent
adverse events (AEs); changes in weight, electrocardiogram, vital signs, and laboratory parameters; and
discontinuation due to AEs.
Results: 915 double-blind study completers were enrolled in the open-label extension study and 902 comprised
the safety population. Mean treatment duration in this study was 10.3 ± 3.5 months. In total, 674 patients (74.7%)
reported at least one AE; in 320 of these patients (47.5%) at least one AE was considered to be possibly or probably
study drug related. The majority of patients reporting AEs (81.9%) had AEs of mild or moderate severity. There were
268 patients (29.7%) who discontinued early, of which 123 (13.6%) were due to AEs.
Patients increasing donepezil dose from 10 mg/day in the double-blind study to 23 mg/day in the extension study
had slightly higher rates of AEs and SAEs than patients who were already receiving 23 mg (78.0% and 16.9% vs
72.8% and 14.0%, respectively). The incidence of new AEs declined rapidly after the first 2 weeks and remained low
throughout the duration of the study.
Conclusion: This study shows that long-term treatment with donepezil 23 mg/day is associated with no new
safety signals. The elevated incidence of AEs in patients increasing the dose of donepezil from 10 mg/day to
23 mg/day was limited to the initial weeks of the study.
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Alzheimer’s disease (AD) is characterized by progressive
impairment of cognitive and functional capacities [1,2].
Current treatments, which provide symptomatic bene-
fits, include acetylcholinesterase inhibitors such as done-
pezil hydrochloride [3,4], and memantine, a glutamate
receptor antagonist [5]. Despite optimal use of these
therapies, symptomatic improvement is limited in mag-
nitude and duration, after which patients continue to de-
cline [6,7].
To address this clear medical need for more effective
symptomatic therapy, a higher dose formulation of
donepezil HCl (23 mg/day) was developed. The 23-mg
dose is formulated as a matrix-type tablet, which pro-
vides a more gradual systemic absorption and longer
time to maximum concentration compared with imme-
diate release formulations [8]. The US FDA recently
granted approval of donepezil 23 mg/day on the basis of
findings from a 24-week, double-blind, randomized con-
trolled trial in 1467 patients with moderate to severe AD
[9] that demonstrated cognitive benefit when the dose of
donepezil was increased to 23 mg/day compared with
continuing on donepezil 10 mg/day.
Here, we report the results of the 1-year open-label ex-
tension of the double-blind trial, which evaluated the
safety and tolerability of donepezil 23 mg/day in AD
patients during long-term treatment.
Methods
The study was conducted between 2007 and 2010 and
included 191 investigators at 179 sites in Asia, Europe,
North America, Oceania, South Africa, and South America.
Patient population
The patient population in the double-blind study has
been previously described [9]. Briefly, the study included
males and females aged 45–90 years with a diagnosis of
probable dementia of the Alzheimer’s type based on the
National Institute of Neurological and Communicative
Diseases and Stroke – Alzheimer’s Disease and Related
Disorders criteria [10] and as defined in the Diagnostic
and Statistical Manual of Mental Disorders Fourth Edi-
tion (code 290.00 or 290.10) [2]; a Mini-Mental State
Evaluation (MMSE) score of 0–20 (moderate to severe
impairment); a severe impairment battery (SIB) score
[11] of ≤ 90 at baseline and screening; a Cornell Scale for
Depression in Dementia [12] score < 12; and who were
otherwise physically healthy. Patients had previously
received donepezil 10 mg/day once daily for ≥ 12 weeks.
Memantine ≤ 20 mg/day was permitted if the dose had
been stable for ≥ 3 months. Patients were randomly
assigned in a 2:1 ratio to receive either a high-dose
donepezil tablet (23 mg once daily) or to remain on
donepezil 10 mg/day.Patients completing the double-blind study were eli-
gible to enter the 12-month extension study if they had
a competent caregiver, provided informed consent, and
were without the following exclusion criteria: ongoing
serious AEs (SAEs); a history of SAEs related to the
study drug during the double-blind study; and no more
than 3 days elapsed since completing the double-blind
study.
Study design
This was a 12-month open-label extension (ClinicalTrials.
gov trial number NCT00566501) of the 24-week, rando-
mized, double-blind, parallel-group study [9]. During the
extension, all patients received donepezil 23 mg/day irre-
spective of the dose received during the double-blind phase.
Clinic visits took place at baseline and at 3, 6, 9, and
12 months.
The protocol, all applicable amendments, and the
informed consent form were approved by an Independent
Ethics Committee (IEC) or Institutional Review Board
(IRB). All participants provided informed consent before
entering the open-label extension study. The trial was
conducted in accordance with the principles of the
Declaration of Helsinki and complied with local laws and
regulations.
Safety assessments
Safety was assessed at the final visit of the double-blind
study (baseline visit of the extension study) and the
3-, 6-, 9-, and 12-month visits of the extension study.
Treatment-emergent AEs (defined as events occurring
after first dose of study drug in the extension study,
or which began during the double-blind study and in-
creased in severity during the extension study), ser-
ious AEs, and concomitant medication were recorded
throughout the study. The investigator assessed AEs for
severity (mild, moderate, severe) and possible or probable
attribution to study drug. Vital signs, weight, and stand-
ard 12-lead electrocardiograms (ECG) were recorded,
blood and urine samples were taken for clinical labora-
tory tests, and physical and neurological examinations
were performed at each visit.
Statistics and data analysis
Safety was analyzed for the safety population, which
consisted of all patients who received at least one dose
of donepezil 23 mg/day during the extension study and
had at least one post-baseline safety assessment.
In addition, two patient subgroups were defined for
the extension study according to whether patients had
received donepezil 10 mg/day or donepezil 23 mg/day
during the double-blind phase. These groups were desig-
nated the 10–23 subgroup and the 23–23 subgroup,
respectively.
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Regulatory Activities (MedDRA), Version 11.1. The
numbers (percentages) of patients with at least one AE,
at least one SAE, and at least one AE leading to discon-
tinuation were summarized. AEs were summarized by
preferred term, severity, and relationship to treatment;
SAEs were summarized by preferred term and relation-
ship to treatment. Deaths were evaluated for possible re-
lationship to study drug. Duration of exposure to study
drug was calculated for the extension study and for the
double-blind and extension studies combined.
All safety-related observations were summarized using
descriptive statistics. No inferential testing was performed.Results
Demographics and baseline characteristics
Basic demographic characteristics are shown in Table 1
(Additional file 1). The mean age of patients was
74.3 ± 8.6 years. Just over one-third of the population
was taking concomitant memantine at the start of the
extension study.Table 1 Baseline†* demographic characteristics
Characteristic Total
Number of safety patients 902










55 to < 65 25.6
65 to < 75 25.5
≥ 75 25.9
Type of residence, %
Lives alone 3.7
Lives with caregiver 80.2
Lives with relative or friend 9.4
Lives in retirement home or assisted living 4.5
Lives in intermediate or skilled nursing facility 1.4
Other 0.8
MMSE, mean (SD) 13.8 (5.9)
Memantine use, % 36.1
MMSE, Mini-Mental State Examination.
†*Extension study baseline.Patient disposition
The patient disposition is shown in Figure 1
(Additional file 2).
Overall, 915 of the 1084 double-blind study comple-
ters were enrolled (84.4%) and 902 comprised the safety
population. The reasons for non-enrollment were not
analyzed. Within the safety population, 570 (63.2%)
patients were in the 23–23 subgroup and 332 (36.8%)
were in the 10–23 subgroup.
Mean duration of treatment in this study was
10.3 ± 3.5 months. Mean duration of treatment in the
combined double-blind and extension studies was
15.9 ± 3.4 months. Mean study drug compliance rate for
the safety population was 96.1%. Overall, there were 268
discontinuations (29.7%), of which 123 (13.6%) were due
to AEs (Additional file 3).
Safety and tolerability
In total, 674 patients (74.7%) reported at least one AE;
in 320 of these patients (47.5%) at least one AE was con-
sidered to be possibly or probably study drug related.
The majority of patients with one or more AE
(552 of 674; 81.9%) reported AEs of mild or moderate
severity. The AEs with the highest incidence were weight
decreased, fall, agitation, urinary tract infection, and ag-
gression (Table 2) (Additional file 4).
The incidences of patients who reported AEs that
are known to be associated with acetylcholinesterase
inhibitors were: decreased weight (11.2%), weight loss
≥ 7% (11.1%), diarrhea (4.3%), nausea (3.5%), syncope
(3.1%), vomiting (2.7%), anorexia (2.4%), bradycardia
(1.2%), and gastrointestinal (GI) bleeding (0.8%, includ-
ing the following terms: GI hemorrhage, hematemesis,
hematochezia, melena, rectal bleeding, and upper GI
hemorrhage). Of the 7 cases of GI bleeding, 5 occurred
in subjects continuing on 23 mg from Study 326
(5/569, 0.9%) and 2 in those transitioning to 23 mg from
10 mg (2/330, 0.6%).
The patients in the 10–23 subgroup had higher rates
of cholinergic AEs (nausea, vomiting, diarrhea) during
the first 4 weeks of the study than those in the 23–23
subgroup (Table 3). Discontinuations due to AEs during
this time period totaled 4.8% in the 10–23 subgroup,
compared with 2.3% in the 23–23 subgroup. However,
after this initial increase in AEs and discontinuations
associated with the upward dose titration in the 10–23
subgroup, the incidence of patients with newly occurring
AEs and discontinuations due to AEs declined rapidly
and remained similarly low in both groups throughout
the remainder of the study (Table 3).
SAEs were reported in 136 patients (15.1%) (Table 4)
(Additional file 5). The most frequent SAEs were syn-
cope, urinary tract infection, and fall. Of the SAEs occur-





Completed n = 423*
(74.2%)
Withdrawn n = 146
(25.6%)
Completed n = 210
(63.3%)
Withdrawn n = 122
(36.7%)
Reasons for discontinuation
   • AE (11.9%)†
   • Patient withdrew consent (5.8%)
   • All other (7.9%)
Reasons for discontinuation
   • AE (17.8%)†
   • Patient withdrew consent (9.0%)
   • All other (9.9%)
Donepezil 10-23
n = 332
Figure 1 Subject disposition. *The completion status for one patient was not determined. †Includes all treatment emergent and treatment
non-emergent AEs and SAEs.
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(1.8%) than in the 23–23 subgroup (1.1%). Overall, 48
(5.3%) patients discontinued due to SAEs. The incidence
of death in the safety population was 2.1% (n = 19); how-
ever, only one death, attributed to hematemesis, was as-
sessed as probably related to study drug. Over the course
of the study there were no changes in laboratory test
values, vital signs, physical exam findings, neurologic
findings, or ECG recordings indicative of a safety signal.
Discussion
Results from this 1-year open-label extension study show
that donepezil 23 mg/day was generally well tolerated.
No safety signals that had not been observed withTable 2 Most frequently occurring adverse events (AE) in
the safety population (incidence≥ 3.0%)
Preferred term Percent of patients
N = 902











Weight increased 3.0donepezil 23 mg in the double-blind study were ob-
served in this extension study, and no worsening of tol-
erability was observed during treatment with 23 mg for
up to a further 12 months among patients who had
already taken donepezil 23 mg for the prior 6 months.
AEs that occurred most frequently were those that may
be associated with AD itself, such as weight loss, falls, or
agitation, and AEs typically associated with administra-
tion of cholinesterase inhibitors, such as gastrointestinal
symptoms. Over 80% of all AEs were mild to moderate
in severity and the rate of SAEs was similar to that
observed in the double-blind study.
Weight loss was the most commonly observed AE
over the course of the extension trial. In the absence of
a control group, it is not possible to attribute this to
study drug based on the findings from this study.
Anorexia and weight loss are important considerations
in AD patients, given their association with mortality
[13]. The effect of donepezil on the body weight of AD
patients has been studied in numerous trials and has
been found to be similar to that observed in placebo-
treated patients [14] (a total of 7–9% of donepezil- and
6–8% of placebo-treated patients experienced clinically
significant weight loss [≥ 7% from baseline] in represen-
tative studies) [15-17]. The larger percentage noted in
this study is likely due to the longer period of observation
compared with most other studies, though it may also be
related to the higher dose of donepezil and the severity of
illness in this patient population. Weight loss is a concern
in this population and should be monitored closely [13].
Bradycardia and GI bleeding are potentially serious
AEs that have been associated with cholinesterase in-
hibitors. The rates of these AEs were very low in the ex-
tension study (1.2% and 0.8%, respectively). All cases of
Table 3 Cumulative incidence of adverse events (AEs) in the safety population by study week
Donepezil 23–23 Donepezil 10–23
N = 570 N = 332
1 week 2 weeks 4 weeks 52 weeks
(total duration)
1 week 2 weeks 4 weeks 52 weeks
(total duration)
Patients with at least 1 AE, % 15.8 18.6 23.2 72.8 20.8 25.9 31.9 78.0
Patients who
discontinued due to AEs, %
0.5 1.6 2.3 11.4 2.4 3.9 4.8 17.5
Patients with AEs, %
Diarrhea 0.4 0.4 0.9 3.5 1.5 2.1 2.7 5.7
Nausea 0.2 0.2 0.2 2.1 3.9 4.2 4.2 6.0
Vomiting 0.0 0.0 0.0 1.6 2.4 2.4 2.7 4.5
Dizziness 0.4 0.4 0.5 1.1 0.9 1.2 1.5 3.6
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that was attributed to study drug. There was no notable
difference in incidence of GI bleeding between the group
continuing on 23 mg from the double-blind study and
the group initiating 23 mg in this open-label study
(0.9% and 0.6%, respectively), nor was the incidence dif-
ferent than that observed in the 23 mg group in the
double-blind study (12/963 [1.1%]) [9]. Moreover, the fa-
tality due to GI bleeding occurred in a patient who
initiated 23 mg in this open-label study. Thus, it appears
that the risk of GI bleeding in patients receiving donepe-
zil 23 mg does not increase in incidence or severity over
a longer duration of treatment with 23 mg.
Overall mortality in this 1-year study was 2.1%, con-
sistent with that observed in the 6-month double-blind
study (0.9%) and with the expected mortality in this
population of elderly patients with moderate or severe
AD [18].
Over the course of the study, 13.6% of patients discon-
tinued due to AEs, including 17.5% of patients in the
10–23 subgroup and 11.4% of the patients in the 23–23
subgroup. This difference in rates of discontinuation
appears to be attributed primarily to the transient
increase in cholinergic-related gastrointestinal AEs
(nausea, vomiting, diarrhea, and anorexia) in the 10–23
subgroup due to titration to the higher dose. This pat-
tern was documented in the initial double-blind study,
where 18.8% and 7.9% of patients discontinued in theTable 4 Serious adverse events (SAEs) in the safety
population (incidence≥1.0%)
Preferred term Percent of patients
N = 902
Patients with at least 1 SAE 15.1
Occurring in ≥ 1% of patients
Syncope 1.3
Urinary tract infection 1.2
Fall 1.0donepezil 23 mg/day and 10 mg/day subgroups, respect-
ively [9,19], and is consistent with other studies with a
dose increase from donepezil 5 mg/day to 10 mg/day
[8]. An increase in cholinergic AEs has been widely
observed with acetylcholinesterase inhibitors when
patients are titrated from a lower to a higher dose regi-
men [20,21]. After the initial peak, the likelihood of ex-
periencing a GI-related AE for the first time during the
study was low and similar in both subgroups. Strategies
to manage AEs when increasing donepezil dose to
23 mg/day should be familiar to healthcare providers
already treating patients with standard donepezil dosing
regimens, and implementation of such strategies may re-
duce the incidence of early discontinuation.
Conclusions
This 1-year extension study of donepezil 23 mg/day in
patients with moderate or severe AD demonstrated no
new safety findings and provides evidence for the accept-
able long-term tolerability of this dosage option.
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